Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3625214 A
Publication typeGrant
Publication dateDec 7, 1971
Filing dateMay 18, 1970
Priority dateMay 18, 1970
Publication numberUS 3625214 A, US 3625214A, US-A-3625214, US3625214 A, US3625214A
InventorsHiguchi Takeru
Original AssigneeAlza Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Drug-delivery device
US 3625214 A
Abstract  available in
Images(1)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 3,184,386 5/1965 Stephenson 3,416,530 12/1968 Ness ABSTRACT: A drug-delivery device for prolongedly delivering drugs to patients according to any predetermined time release profile, e.g., increasing, decreasing, constant, pulsing, sinusoidal, and like patterns of release, is fabricated by applying a drug coating of varying or uniform thickness to a relatively drug-impermeable film soluble in body fluids and thence rolling said coated film about itself in spiral or jeliyroli fashion. Upon administration to the body, the outermost extremities of the film gradually erode at a predetermined rate in body fluids thus exposing coextensive extremities of the drug coating, also soluble in body fluids, and drug is released to the tissues of the body. Suitable design of the drug coating along the spiral, e.g., of varying thickness, etc. provides for the aforesaid release patterns as the device disintegrates.

PATENTEDDEC nan 35251214 INVENTOR. Takeru Higuchi Attorney nnuc-nnuvnav DEVICE BACKGROUND OF THE INVENTION This invention relates to a device for delivering drugs to patients according to a programmed schedule and, more especially, to a device which can deliver drugs according to any desired program of release which may be therapeutically desired.

In the pharmaceutical field, most prolonged or sustained action medicators have had as their objective to release medication at a constant rate. However, many programs of therapy require that the quantity of medication administered vary with time. For example, in antibiotic therapy, it is common to administer a large initial dose of drug followed by smaller doses. Conversely, in desensitizing against allergens, therapeutic regimes often call for dose of the allergen to progressively increase over the time of treatment. More complex regimes, in which the dose of medication varies through periodic high and low points, are also known. In general, these therapeutic programs are practiced by periodically administering different amounts of medication in separate dosage forms. Such practice requires frequent acts by the patient or trained attendant and departures from the therapeutic program often occur. Thus, a need exists for a drug-delivery device that can provide any desired time profile for drug administration.

SUMMARY OF THE INVENTION Accordingly, it is a primary object of this invention to pro vide a device for delivering drugs to patients according to any predetermined time release profile.

In attaining the objects of this invention, one feature resides in the application of a drug coating of varying or uniform thickness to a relatively impermeable film soluble in body fluids. To provide the drug-delivery unit, the coated film is spirally wound or rolled about itself in jellyroll fashion. When the device is physically inserted or implanted in the body or administered via the gastrointestinal tract, the film gradually erodes or dissolves at a predetennined rate in body fluids thus exposing the drug coating. By suitable design of the film and of the drug coating, which itself dissolves in body fluids, one can obtain any desired release pattern including increasing, decreasing, pulsing, constant, sinusoidal, etc.

Other objects, features and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings, and wherein like reference numerals are used to indicate like or equivalent parts.

BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:

FIG. 1 is a side view of the coated substrate precursor structure of a drug-delivery device of this invention;

FIG. la is a top view of a drug-delivery device of this invention, formed from the structure of FIG. 1;

FIG. lb is a side view of the structure of FIG. la;

FIG. 2 is a side view of a coated substrate precursor structure of another drug-delivery device of this invention;

FIG. 2a is a top view of another drug-delivery device of this invention, formed from the structure of FIG. 2;

FIG. 2b is a top view of another drug-delivery device of this invention, also formed from the structure of FIG. 2;

FIG. 20 is a side view of the structures of both FIG. 2a and FIG. 2b;

FIG. 3 is a side view of a coated substrate precursor structure of yet another drug-delivery device of this invention;

FIG. 3a is a top view of yet another drug-delivery device of this invention, formed from the structure of FIG. 3;

FIG. 3b is a side view of the structure of FIG. 3a;

FIG. 4 is a side view of a coated substrate precursor structure of still another drug-delivery device of this invention;

FIG. 4a is a top view of still another drug-delivery device of this invention, formed from the structure of FIG. 4;

FIG. 4b is a side view of the structure of FIG. 4a;

DETAILED DESCRIPTION OF THE INVENTION This invention has for its essence an assemblage of relatively impermeable film separating slowly soluble, medicament-containing matrix composition. Referring particularly to FIGS. I and la, a relatively impermeable film 10 is shown which dissolves at a slow predetermined rate in body fluids. The film 10 is coated with a medicament Ill containing matrix composition 12 of constant thickness, which matrix is soluble in body fluids (FIG. I).

The coated film is next spirally wound or rolled about itself in jellyroll" fashion to provide the drug-delivery device 13 of FIGS. Ia and lb.

To use the drug-delivery device of this invention, it is either physically inserted or surgically implanted in the body or is administered via the gastrointestinal tract. As the film is eroded away by the action of either gastrointestinal tissue or other body fluids, the drug matrix layer becomes exposed and it too erodes, thus releasing the drug to the tissues of the body. When the matrix layer is thin, relatively small amounts of medication are released per amount of film eroded. Conversely, if the matrix layer is thick the amount of medicament released will be enhanced. By adjusting the thickness of the matrix or the concentration of drug therein, any desired time release profile can be programmed.

By use of the drug-delivery device of FIGS. la and lb which is comprised of a drug-matrix coating of constant thickness, there is provided a drug dosage unit which can exhibit a constant slow rate of release of drug.

In FIG. 2 a relatively impenneable film I0 is also shown which dissolves very slowly in body fluids. However, in this embodiment the said film I0 is coated with a medicament I1 containing matrix composition 12 of uniformly varying thickness, namely, the drug or matrix layer is spread thin at a proximal end of the surface of the film but uniformly progressively thicker across to the distal end of the surface of the film.

It will thus be appreciated that, depending upon from which end the assemblage is wound about itself, there can be conveniently prepared drug-delivery devices which will provide constantly decreasing slow rate of release of drug (FIG. 2a) or constantly increasing slow rate of release of drug (FIG. 2b). In either event such devices would be identical in side plan view (FIG. 2c).

As described and illustrated above, the drug-delivery device of this invention may be comprised of a drug-matrix layer such as to program any desired time release profile, and two other of such forms are illustrated in FIGS. 3, 3a, 3b, 4, 4a and 4b, with the FIGS. 3 depicting a unit which provides a pulsing release pattern and the FIGS. 41 a unit which provides a sinusoidal release pattern.

Moreover, even though in the FIGS. of the drawing cylindrical structures are shown, it is apparent that flattened (FIG. 5) or other configurations can be easily provided. The drugdelivery device of the invention is also advantageously capped at either end with a material 14 slowly soluble in body fluids so as to prevent even the slightest amount of drug from prematurely exuding out of said ends (see FIG. 6).

In many instances, it is desirable to provide for release of the drug immediately upon administration of the device. This can be achieved by coating the preformed device, as illustrated in any of FIGS. 10, 2a, 2b, 3a, da and 5, with a layer of the matrix 112 containing drug 11. Alternatively, as illustrated in FIG. '7, film It) can be coated with medicament 11 containing matrix composition 12 on both face surfaces thereof. Upon rolling this coated film about itself, the resulting device will bear a drug-containing coating on its exterior surface (FIG. 7a). In either event, the resulting device initially will release drug by dissolution of the exteriorly exposed coating of the matrix. Thereafter, the film will dissolve, eventually releasing drug disposed within the interior of the spirally wound device.

The film or carrier materials 10 are flexible and relatively resistant to erosion in body fluids to provide for medicating action over a prolonged period of time and are preferably polymeric in nature. Exemplary materials include polymers of the following three general classes: (1 those which slowly dissolve in body fluids, for example, gelatin, glycerinated gelatin, formalin treated gelatin, collagen, polyvinylalcohol, and the like; (2) those which hydrolyze in body fluids, for example, the polymeric, essentially linear, dibasic acid anhydrides of the formula:

especially the polyanhydride polymers of sebacic and azelaic acids, polyhydroxyacetic acid such as described in U.S. Pat. Nos. 2,668,162 and 2,676,945, and polysulfite polymers; and (3) polymers cleaved by enzymes present in body fluids. for example, chitin, which is enzymatically cleaved by lysozyme.

The polyanhydride polymers of theabove type (2) can be conveniently prepared by condensing the respective dibasic acids in the presence of SOCl,, benzene and ethyl acetate.

The film or carrier material should be relatively impermeable to passage of the drug by difiusion or leaching. Otherwise, the rate of release of the drug will depend, at least in part, upon diffusion through the film rather than upon erosion of the film and matrix. Selection of appropriate membrane materials will be dependent on the particular drug to be used, and those skilled in the art can readily make the appropriate choices.

Matrix materials used in fabricating the drug coating of constant or varying thickness are soluble in body fluids. The drug matrix substance must erode faster than the film such that, when physically inserted or implanted in the body or administered via the gastrointestinal tract, the film first erodes or dissolves in body fluids thus exposing the drug coating which thence itself erodes or dissolves and hence provides a slow rate of release of drug, albeit the erosion or dissolution is more rapid than that of the film material. In this manner, erosion or dissolution of the film is the rate controlling step for drug administration; for once the film erodes at its predetennined rate, the drug is released relatively rapidly by dissolution of the matrix. Exemplary matrix materials include polyvinylpyrrolidone, water soluble starch, gum acacia, gum tragacanth, or the like, or even those film materials hereinbefore delineated, so long as the requirement is observed that the selected drug matrix substance must erode or dissolve faster than the selected film.

Any of the drugs used to treat the body can be incorporated in the drug layer of the drug-delivery device of this invention. Drug is used herein in its broadest sense as including any composition or substance that will produce a pharmacologic response.

Suitable drugs for use in therapy with the device of the invention include without limitation:

l. Protein drugs such as insulin;

2. Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;

3. Vaccines such as smallpox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyptheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;

4. Antiinfectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other antiinfectives including nitrofurazone and sodium propionate;

5. Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;

6. Antiallergenics such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2lphosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;

7. Decongestants such as phenylcphrine, naphazoline, and tetrahydrazoline;

8. Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide, and demecarium bromide;

such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine;

l0. Sympathomimetics such as epinephrine;

l l. Sedatives and Hypnotics such as pentabarbital sodium, phenobarbital, secobarbital sodium, codeine, (abromoisovaleryl) urea, carbromal;

l2. Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate;

13. Tranquilizers such as reserpine, chlorpromayline, and thiopropazate;

l4. Androgenic steroids such as methyltestosterone and fluorymesterone;

15. Estrogens such as estrone, l7 B-estradiol, ethinyl estradiol, and diethyl stilbesterol;

l6. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinonc, ethisterone, norethynodrel, l9- nor-progesterone, norethindrone, medroxyprogesterone and 17 B-hydroxy-progesterone;

l7. Humoral agents such as the prostaglandins, for example PGE PGE and PGF l8. Antipyretics such as aspirin, sodium salicylate, and salicylamide;

l9. Antispasmodics such as atropine, mcthantheline, papaverine, and methscopolamine bromide;

20. Antimalarials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;

21. Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and chlorophenazine;

22. Cardioactive agents such as dibenzhydroflumethiazide, flumethiazide, chlorothiazide, and aminotrate;

23. Nutritional agents such as vitamins, essential amino acids and essential fats.

Other drugs having the same or different physiological activity as those recited above can be employed in drug-delivery devices within the scope of the present invention.

Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc., can be employed.

The amount of drug incorporated in the drug-delivery device varies widely depending on the particular drug, the desired therapeutic elTect, and the time span for which it takes the film barrier and matrix material to erode or dissolve. Since a variety of devices in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the device. The lower limit too will depend on the activity of the drug and the time span of its release from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the device.

To prepare the drug-delivery device of the invention, the drug is mixed with the matrix material either at ambient or elevated temperatures to form a settable mixture. The settable mixture, whether a dispersion or true solution, is then simply spread on the film substrate in constant or varying thicknesses (see the FIGS. of the drawing) and allowed to set, for example, by drying or hardening. The coated film is next spirally wound or rolled about itself in jellyroll to provide the subject device.

In applying the drug-containing matrix to the film, the drug release profile of the device is determined. in most instances, a matrix of uniform drug concentration is applied over one entire surface of the film, at a constant or varying thickness. However, the matrix can be printed onto the film in various patterns, providing different rates of drug release. In addition, different portions of the film can be coated with matrix portions having different drug concentration. in each of these ways, the rate of release of drug from the device can be controlled and a wide variety of release patterns obtained.

The drug-delivery device can be fabricated in any convenient shape for either physical insertion or implantation in the body or for administration via the gastrointestinal tract. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular drug to be supplied to the body to elicit the desired pharmacologic response, as well as by the form the dosage unit takes, for example, implantate, suppository, peroral pellet, oral bolus, vaginal pessory, buccal or sublingual lozenge, ocular insert (e.g. as described in US. Pat. No. 3,416,530), the like. Likewise with respect to the upper limit on the size of the device. One of the prime advantages of the dosage form of the invention over the capsule types of the prior art is that any inadvertent flaw in the protective film barrier will not suddenly release the entire drug content. Another advantage, if used as an implantate or the like, is the total disappearance of the film barrier when its function has been completed. Likewise as regards the drug matrix material.

It too will be appreciated that the principle of providing any predetermined time release profile can be embodied in devices other than drug-delivery devices, namely, in any device where it is desired to provide for the prolonged release of any active ingredient according to any desired release pattern.

While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, those skilled in the art will appreciate that various modifications, changes, and omissions in the drug-delivery device illustrated and described can be made without departing from the spirit of the invention. It is the intention, therefore, to be limited only by the scope of the following claims.

What is claimed is:

l. A drug-delivery device for prolongedly delivering drugs according to any predetermined time release profile comprised of a spirally rolled substrate, said substrate being comprised of a relatively drug impermeable, flexible film erodible in body fluids and being coated with a drug-containing matrix composition, which matrix itself is erodible in body fluids.

2. The drug-delivery device as defined by claim 1, wherein the matrix composition is more rapidly erodible in body fluids than said film.

3. The drug-delivery device as defined by claim 1, wherein the drug is uniformly distributed throughout the matrix composition.

4. The drug-delivery device as defined by claim 3, wherein the drug coating is of constant thickness along the spiral.

5. The drugelivery device as defined by claim 3, wherein the drug coating is of varying thickness.

6. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating increases along the spiral.

7. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating decreases along the spiral.

8. The drug-delivery device as defined by claim 3, wherein the drug coating is of sinusoidal thickness along the spiral.

9. The drug-delivery device as defined by claim 5, wherein the film is comprised of a polymeric material which slowly dissolves in body fluids.

10. The drug-delivery device as defined by claim 3, wherein the film is comprised of polymeric material which hydrolyzes in body fluids.

11. The drugdelivery device as defined by claim 3, wherein the membrane is comprised of polymeric material which is cleaved by enzymes present in body fluids.

112. The drug-delivery device as defined by claim 1 bearing an external coating of said drug-containing matrix composition.

13. A device for prolongedly delivering active ingredient to a given fluid environment according to any predetermined time release profile comprised of a spirally rolled substrate said substrate being comprised of a relatively active ingredient impermeable, flexible film erodible in a given fluid environment, said fllm being coated with an active ingredient containing matrix composition, which matrix itself is erodible in said given fluid environment.

14. The method of prolongedly delivering drug to a patient according to any predetermined time release profile comprising administering to said patient the drug-delivery device as defined by claim ll.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2099402 *Jan 17, 1934Nov 16, 1937Pratt Food CompanyPill or tablet
US2928770 *Nov 28, 1958Mar 15, 1960Bardani Frank MSustained action pill
US3184386 *Aug 29, 1962May 18, 1965Burroughs Wellcome CoProlonged action medicinal tablets
US3416530 *Mar 2, 1966Dec 17, 1968Richard A. NessEyeball medication dispensing tablet
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3826258 *Feb 7, 1972Jul 30, 1974Abraham SGradual release medicine carrier
US3887699 *Dec 29, 1970Jun 3, 1975Yolles SeymourBiodegradable polymeric article for dispensing drugs
US3888975 *Dec 27, 1972Jun 10, 1975Alza CorpErodible intrauterine device
US3892238 *Jan 14, 1974Jul 1, 1975Abbott LabDrug supporting anchor
US3898986 *Dec 27, 1972Aug 12, 1975Alza CorpBiotransformable intrauterine device
US3926188 *Nov 14, 1974Dec 16, 1975Alza CorpLaminated drug dispenser
US3960150 *Sep 15, 1975Jun 1, 1976Alza CorporationBioerodible ocular device
US3961628 *Apr 21, 1975Jun 8, 1976Alza CorporationOcular drug dispensing system
US3971367 *Jun 4, 1975Jul 27, 1976Alza CorporationIntrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3981303 *Jul 31, 1975Sep 21, 1976Alza CorporationBioerodible ocular device
US3986510 *Aug 1, 1975Oct 19, 1976Alza CorporationBioerodible ocular device
US3993071 *Jul 24, 1975Nov 23, 1976Alza CorporationBioerodible ocular device
US3993073 *Mar 3, 1975Nov 23, 1976Alza CorporationNovel drug delivery device
US4083741 *Jul 27, 1976Apr 11, 1978Hoffmann-La Roche, Inc.Novel dosage form
US4126502 *Apr 29, 1977Nov 21, 1978Hoffmann-La Roche Inc.Manufacture of pharmaceutical dosage forms
US4126503 *Apr 29, 1977Nov 21, 1978Hoffmann-La Roche Inc.Manufacture of pharmaceutical dosage forms
US4135514 *Mar 9, 1977Jan 23, 1979Alza CorporationOsmotic releasing system for administering ophthalmic drug to eye of animal
US4142526 *Mar 9, 1977Mar 6, 1979Alza CorporationOsmotic releasing system with means for changing release therefrom
US4228149 *May 30, 1978Oct 14, 1980Beecham Group LimitedSustained release compositions
US4308250 *Dec 9, 1980Dec 29, 1981Beecham Group LimitedFor oral administration to ruminants
US4439183 *May 13, 1982Mar 27, 1984Alza CorporationParenteral agent dispensing equipment
US4521211 *Feb 3, 1984Jun 4, 1985Alza CorporationParenteral agent dispensing equipment
US4540408 *Apr 29, 1982Sep 10, 1985Smith And Nephew Associated Companies LimitedApplicators for pharmacologically active agents, their preparation and use
US4548598 *Feb 3, 1984Oct 22, 1985Alza CorporationParenteral agent dispensing equipment
US4576604 *Mar 4, 1983Mar 18, 1986Alza CorporationOsmotic system with instant drug availability
US4673405 *Jan 8, 1986Jun 16, 1987Alza CorporationOsmotic system with instant drug availability
US4698062 *Oct 30, 1985Oct 6, 1987Alza CorporationMedical device for pulsatile transdermal delivery of biologically active agents
US4883666 *Apr 29, 1987Nov 28, 1989Massachusetts Institute Of TechnologyControlled drug delivery system for treatment of neural disorders
US4886870 *Feb 15, 1985Dec 12, 1989Massachusetts Institute Of TechnologyBioerodible articles useful as implants and prostheses having predictable degradation rates
US4891225 *Jan 21, 1986Jan 2, 1990Massachusetts Institute Of TechnologySustained release
US4906474 *May 21, 1984Mar 6, 1990Massachusetts Institute Of TechnologyBioerodible polyanhydrides for controlled drug delivery
US4946929 *Jun 15, 1987Aug 7, 1990Massachusetts Institute Of TechnologyBiocompatible polyanhydrides
US5079006 *Jul 13, 1988Jan 7, 1992Aprex CorporationPharmaceutical compositions containing a magnetically detectable material
US5114719 *Sep 14, 1989May 19, 1992Sabel Bernhard APolymer matrix for drug delivery of biologically active molecules
US5167962 *Aug 8, 1991Dec 1, 1992Southwest Research InstituteRelease at desired location in intestine
US5236734 *Mar 16, 1992Aug 17, 1993Fuisz Technologies Ltd.Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5238696 *May 6, 1992Aug 24, 1993Fuisz Technologies Ltd.Method of preparing a frozen comestible
US5268110 *Aug 27, 1992Dec 7, 1993Fuisz Technologies Ltd.Oil removing method
US5279849 *May 12, 1992Jan 18, 1994Fuisz Technologies Ltd.Melt spinning
US5286513 *Jun 22, 1993Feb 15, 1994Fuisz Technologies Ltd.Proteinaceous food product containing a melt spun oleaginous matrix
US5326568 *Apr 30, 1992Jul 5, 1994Giampapa Vincent CImplanting insert having drug-containing, biodegradable concentric shells
US5348758 *Oct 20, 1992Sep 20, 1994Fuisz Technologies Ltd.Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5374447 *Dec 6, 1993Dec 20, 1994Fuisz Technologies Ltd.Exchanging a portion of fat in meat product with oleaginous containing matrix formed by vegetable oils or animal fats and oils and sugar
US5380473 *Oct 23, 1992Jan 10, 1995Fuisz Technologies Ltd.Process for making shearform matrix
US5387431 *Mar 5, 1992Feb 7, 1995Fuisz Technologies Ltd.Saccharide-based matrix
US5407676 *Dec 24, 1992Apr 18, 1995Fuisz Technologies Ltd.Hydrophilic form of perfluoro compounds and a method of manufacture
US5427804 *Mar 15, 1994Jun 27, 1995Fuisz Technologies Ltd.Low-fat edible proteins with maltodextrins and low-saturate oils
US5429836 *Jul 29, 1993Jul 4, 1995Fuisz Technologies Ltd.Maltodextrin and emulsifier feed and matrix for foods
US5445769 *Jun 27, 1994Aug 29, 1995Fuisz Technologies Ltd.Spinner head for flash flow processing
US5456932 *Apr 22, 1994Oct 10, 1995Fuisz Technologies Ltd.Adding fructose to reduce heat needed to create flash flow conditions
US5464935 *Feb 6, 1995Nov 7, 1995Centocor, Inc.Peptide inhibitors of selectin binding
US5472731 *Mar 22, 1995Dec 5, 1995Fuisz Technologies Ltd.Protein based food product
US5490993 *Mar 24, 1995Feb 13, 1996Fuisz Technologies Ltd.Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof
US5494677 *Jun 28, 1993Feb 27, 1996Giampapa; Vincent C.Tissue-specific implantable therapeutic agent delivery system
US5501858 *Sep 10, 1993Mar 26, 1996Fuisz Technologies Ltd.Rapidly dispersable compositions containing polydextrose
US5503862 *May 26, 1995Apr 2, 1996Fuisz Technologies Ltd.Reducing temperature by mixing in fructose, maltodextrin and/or polydextrose
US5516537 *May 4, 1993May 14, 1996Fuisz Technologies Ltd.Frozen comestibles
US5518551 *Sep 10, 1993May 21, 1996Fuisz Technologies Ltd.Spheroidal crystal sugar and method of making
US5518730 *Jun 3, 1992May 21, 1996Fuisz Technologies Ltd.Biodegradable controlled release flash flow melt-spun delivery system
US5520859 *Apr 8, 1994May 28, 1996Fuisz Technologies Ltd.Method for flash flow processing having feed rate control
US5545409 *Apr 5, 1994Aug 13, 1996Massachusetts Institute Of TechnologyShaped matrix of polyanhydride or polyorthoester and a chondrogenic or osteogenic bioactive protein
US5549917 *Jun 7, 1995Aug 27, 1996Fuisz Technologies Ltd.Flash flow formed solloid delivery systems
US5556652 *Aug 5, 1994Sep 17, 1996Fuisz Technologies Ltd.Comestibles containing stabilized highly odorous flavor component delivery systems
US5567439 *Nov 4, 1994Oct 22, 1996Fuisz Technologies Ltd.Delivery of controlled-release systems(s)
US5576042 *Mar 2, 1994Nov 19, 1996Fuisz Technologies Ltd.High intensity particulate polysaccharide based liquids
US5582855 *Jul 1, 1994Dec 10, 1996Fuisz Technologies Ltd.Flash flow formed solloid delivery systems
US5587198 *May 31, 1995Dec 24, 1996Fuisz Technologies Ltd.Positive hydration method of preparing confectionery and product therefrom
US5593502 *Jun 6, 1995Jan 14, 1997Fuisz Technologies Ltd.Method of making crystalline sugar and products resulting therefrom
US5597416 *Oct 7, 1993Jan 28, 1997Fuisz Technologies Ltd.Method of making crystalline sugar and products resulting therefrom
US5597608 *Dec 28, 1994Jan 28, 1997Fuisz Technologies Ltd.Feedstock subjected to force and heating conditions to induce flash flow; foods, drugs
US5601076 *Jun 5, 1995Feb 11, 1997Fuisz Technologies Ltd.Spheroidal polycrystallite having continuous three-dimensional structure comprising small crystallites arranged around spheroidal center
US5601835 *Jan 12, 1994Feb 11, 1997Massachusetts Institute Of TechnologyInsertion into central nervous system
US5602230 *May 10, 1995Feb 11, 1997Centocor, Inc.Peptide inhibitors of selectin binding
US5618785 *Jun 1, 1995Apr 8, 1997Centocor, Inc.Antiischemic agents, antitumor agents, antiarthritic agents
US5622719 *May 23, 1996Apr 22, 1997Fuisz Technologies Ltd.Mixing additive with uncured shearform carrier matrix, molding, crystallization
US5624684 *May 13, 1992Apr 29, 1997Fuisz Technologies Ltd.Enzyme systems
US5629009 *Aug 7, 1996May 13, 1997Massachusetts Institute Of TechnologyInducing chondrogenesis and osteogenesis by implanting shaped polyanhydride or polyorthoester matrix with bioactive substance, i.e., demineralized bone protein, tgf-beta, egf, fgf or pdgf
US5633027 *Jun 7, 1995May 27, 1997Fuisz Technologies Ltd.Solid delivery system; mixture of flavored oils and triglycerides
US5651987 *Aug 27, 1993Jul 29, 1997Fuisz Technologies Ltd.Ulcer prevention and treatment composition
US5654003 *Feb 10, 1994Aug 5, 1997Fuisz Technologies Ltd.Process and apparatus for making tablets and tablets made therefrom
US5654273 *Sep 22, 1994Aug 5, 1997Children's Medical Center CorporationSynducin mediated modulation of tissue repair
US5660848 *Nov 2, 1994Aug 26, 1997The Population Council, Center For Biomedical ResearchSubdermally implantable device
US5660851 *Jun 5, 1995Aug 26, 1997Yissum Research Development Company Of The Hebrew Univ. Of JerusalemCovalent attachmentof a carboxylic acid-containing active material through anhydride bonds to a polymer that contains pendant carboxylic acid groups; drug delivery
US5695993 *Aug 12, 1994Dec 9, 1997Oklahoma Medical Research FoundationCloning and regulation of an endothelial cell protein C/activated protein C receptor
US5709876 *Jun 7, 1995Jan 20, 1998Fuisz Technologies Ltd.Saccharide-based matrix
US5710123 *Dec 13, 1993Jan 20, 1998Centocor, Inc.Peptide inhibitors of selectin binding
US5713852 *Jun 7, 1995Feb 3, 1998Alza CorporationOral dosage and method for treating painful conditions of the oral cavity
US5728397 *Feb 4, 1997Mar 17, 1998Fuisz Technologies Ltd.Polydextrose product and process
US5733577 *Aug 16, 1996Mar 31, 1998Fuisz Technologies Ltd.Crystallization of a quick-dissolving shearform matrix, mixing with a time-release drug delivery system to form flowable microparticles and compacting
US5744180 *Oct 23, 1996Apr 28, 1998Fuisz Technologies Ltd.Comestibles containing stabilized highly odorous flavor component delivery systems
US5753617 *Sep 8, 1993May 19, 1998Centocor, Inc.Peptide inhibitors of cellular adhesion
US5756115 *Jun 7, 1995May 26, 1998The Population Coucil, Center For Biomedical ResearchContraceptive method using a subdermally implantable device
US5759539 *Jun 6, 1995Jun 2, 1998Georgia Research Foundation, Inc.Oxidizing ethanol to acetate in the blood
US5804247 *Dec 20, 1996Sep 8, 1998Fuisz Technologies Ltd.Mixing together a saccharide based shearform matrix comprising magnesium and calcium salt and hydrated hydrobonding agent selected from food grade gums, gelatin and mixture, hydration to provide cohesiveness and lubricity
US5824342 *Apr 9, 1996Oct 20, 1998Fuisz Technologies Ltd.Flash flow formed solloid delivery systems
US5827563 *Jan 13, 1997Oct 27, 1998Fuisz Technologies Ltd.Fondant cream containing polycrystalline sugar having uniform controlled particle size and three-dimensional structure
US5843884 *Nov 15, 1995Dec 1, 1998Oklahoma Medical Research FoundationC9 complement inhibitor
US5843922 *Jun 11, 1996Dec 1, 1998Fuisz Technologies Ltd.Preparation of oligosaccharides and products therefrom
US5849900 *Mar 28, 1995Dec 15, 1998Max-Planck-Gesellschaft Zur Forderung Der Wissenschafter E.V.Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
US5851552 *Aug 16, 1996Dec 22, 1998Fuisz Technologies, Ltd.Delivery of controlled-release system(s)
US5851553 *Dec 19, 1996Dec 22, 1998Fuisz Technologies, Ltd.Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5853760 *Dec 2, 1994Dec 29, 1998Lts Lohmann Therapie-Systeme Gmbh & Co. KgDevice for the controlled release of active substances
US5853762 *Aug 16, 1996Dec 29, 1998Fuisz Technologies LtdDelivery of controlled-release system(s)
US5858385 *Jul 21, 1997Jan 12, 1999The Trustees Of The Stevens Institute Of TechnologyMicroporous hollow fiber membrane having pores filled with water or solvent, fiber lumen filled with solvent or water and pest control substance or fragrance which partitions in pores and diffuses out
US5859227 *Feb 20, 1997Jan 12, 1999Bearsden Bio, Inc.Binding sites for proteins involved in post-transcriptional regulation in eukaryotic cells; for potential drug targets and cloning of heterologous proteins
US5866163 *Dec 19, 1996Feb 2, 1999Fuisz Technologies Ltd.Quick dissolving active material
US5871781 *Dec 19, 1996Feb 16, 1999Fuisz Technologies Ltd.Apparatus for making rapidly-dissolving dosage units
US5888982 *Mar 31, 1997Mar 30, 1999President And Fellows Of Harvard CollegeRegulation of vascular smooth muscle cell heme oxygenase-1
US5895664 *Jun 14, 1994Apr 20, 1999Fuisz Technologies Ltd.Process for forming quickly dispersing comestible unit and product therefrom
US5898066 *Aug 26, 1994Apr 27, 1999Children's Medical Center CorporationTrophic factors for central nervous system regeneration
US5916876 *Dec 22, 1994Jun 29, 1999Centocor, Inc.Peptide inhibitors of leukocyte adhesion
US5925333 *Nov 15, 1995Jul 20, 1999Massachusetts Institute Of TechnologyScreening for compounds that alter the binding by scavengers
US5962322 *Nov 15, 1996Oct 5, 1999Massachusetts Institute Of TechnologyMethods for modulation of cholesterol transport
US6001990 *Jun 7, 1995Dec 14, 1999The General Hospital CorporationAntisense inhibition of hepatitis C virus
US6004749 *Jul 31, 1997Dec 21, 1999Message PharmaceuticalsDetection of interactions between rna binding proteins and each of amyloid precursor protein untranslated region
US6020002 *Nov 5, 1997Feb 1, 2000Fuisz Technologies Ltd.Delivery of controlled-release system(s)
US6107029 *Jul 31, 1996Aug 22, 2000Message Pharmaceticals, Inc.Detecting protein bound nucleic acids; forming binding solution, heating solution, denaturing the nucleic acids in solution, cooling solution, adding proteins, detecting interactions between the proteins and ribonucleic acids
US6110481 *Mar 4, 1994Aug 29, 2000Trustees Of The Stevens Institute Of TechnologyA controlled release dispenser employing microporous membranes with or without a nonporous coating and aqueous-organic partitioning of the bioreactive substances such as pesticides, hormones, nutrients and fragrances to humans or animals
US6124267 *Apr 20, 1998Sep 26, 2000Southpac Trust Internationals, Inc.O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6129926 *May 13, 1992Oct 10, 2000Fuisz Technologies Ltd.Flash flow processing of thermoplastic polymers and products made therefrom
US6196993Apr 19, 1999Mar 6, 2001Eyelab Group, LlcOphthalmic insert and method for sustained release of medication to the eye
US6200751Nov 7, 1997Mar 13, 2001Oklahoma Medical Research FoundationCell preferential regulatory sequences; for the control of transcription from heterologous nucleotide sequences; for use in gene therapy
US6203813Oct 9, 1998Mar 20, 2001Lance L. GoobermanOpiate antagonist, steroidal antiinflammatory agent and carrier; sustained release; drug abuse treatment
US6284729May 6, 1998Sep 4, 2001Children's Medical Center CorporationMethods and reagents for regulating obesity
US6299875Jun 4, 1998Oct 9, 2001Panacea Pharmaceuticals, LlcMethods to block IGE binding to cell surface receptors of mast cells
US6306428Apr 13, 1998Oct 23, 2001Roehm Gmbh Chemische FabrikControlled active substance release is accomplished with rolled or folded layers of a polymer film, that contain a pharmaceutically active substance
US6309639Aug 9, 2000Oct 30, 2001The Board Of Regents Of The University Of OklahomaAdministering an antibody to a protein component or to a carbohydrate-protein component of p-selectin glycoprotein ligand, the glycoprotein ligand comprising a fucosylated sialylated glycoprotein containing sialyl lewis x antigen
US6350859Feb 2, 1999Feb 26, 2002Massachusetts Institute Of TechnologyClass BI and CI scavenger receptors
US6399064Oct 29, 1998Jun 4, 2002Oklahoma Medical Research FoundationCloning endothelial cells and protein c
US6407236Aug 23, 1999Jun 18, 2002Medco Research, Inc.Tumor diagnosis; antiinflammatory agents; antiischemic agents; antidepressants
US6410508Oct 7, 1999Jun 25, 2002Med College Georgia Res InstGlucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6448253Sep 16, 1998Sep 10, 2002King Pharmaceuticals Research And Development, Inc.Adenosine A3 receptor modulators
US6506382Oct 29, 2001Jan 14, 2003The Board Of Regents Of The University Of OklahomaMethod for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
US6667036Nov 18, 2002Dec 23, 2003The Board Of Regents Of The University Of OklahomaAdministering antibody to a protein component or to a carbohydrate-protein component of P-selectin glycoprotein ligand for therapy of rheumatoid arthritis
US6919373Feb 19, 1999Jul 19, 2005Alza CorporationMethods and devices for providing prolonged drug therapy
US6921825Apr 26, 2002Jul 26, 2005King Pharmaceuticuals Research & Development, Inc.Pyrazolo-triazolo- pyrimidine, triazolo-triazolo-pyrimidine and imidazolo-triazolo-pyrimidine derivatives useful for the treatment of hypertension, inflammation, mast cell degranulation, cardiac hypoxia, and ischemia
US6930129Mar 8, 2001Aug 16, 2005Alza CorporationOrally administering a dosage form containing a central nervous system-acting drug in a pharmaceutically acceptable carrier, wherein said dosage release the drug at an ascending release rate for an extended time period
US6953568Aug 25, 1998Oct 11, 2005Oklahoma Medical Research FoundationAdministering biological conjugates that bind preferentially to endothelial protein C receptor(EPCR), to endothelial cells of vascular systems; genetic translocation; drug delivery
US7045350Aug 29, 2002May 16, 2006Mount Sinai School Of Medicine Of New York UniversityAlternatively spliced circulating tissue factor
US7063843Aug 20, 1999Jun 20, 2006Oklahoma Medical Research FoundationCloning and regulation of an endothelial cell protein C/activated protein C receptor
US7078511Jun 19, 1995Jul 18, 2006Massachusette Institute Of Technologynucleic acid molecule encoding Hamster scavenger receptor BI (HaSR-BI) which has high affinity for low density lipoproteins (LDL) and acylated LDL, expressed in adipocytes; antilipemic, anticholesterol agents; receptor binding assay; drug screening
US7166568Feb 9, 1998Jan 23, 2007Oklahoma Medical Research FoundationCompositions and methods to inhibit formation of the C5b-9 complex of complement
US7208467Jun 7, 2002Apr 24, 2007Monty KriegerAdministering a compound altering transfer of cholesterol or cholesteryl ester from high density lipoprotein or other lipoproteins via SR-BI to liver or steroidogenic tissues or compounds blocking oxidative modification of LDL
US7241457 *Sep 29, 2004Jul 10, 2007Alza CorporationOsmotically driven active agent delivery device providing an ascending release profile
US7306580Apr 16, 2003Dec 11, 2007Cook IncorporatedMedical device with therapeutic agents
US7361684May 16, 2002Apr 22, 2008Massachusetts Institute Of TechnologyScreening of compounds for treatment of atherosclerosis and heart attack
US7514592Apr 5, 2005Apr 7, 2009Massachusetts Institute Of Technologytransgenic rodents genetically engineered to knock out gene expression of active scavenger receptor class BI (SR-BI) and having apolipoprotein E activity or expression decreased to 2-5% of normal levels; models of cardiovascular disoders induced by feeding a lipid enriched diet
US7780647Oct 31, 2007Aug 24, 2010Cook IncorporatedMedical device with therapeutic agents
US7785632Sep 15, 2004Aug 31, 2010Ordway Research Institute, Inc.angiogenesis inhibitors; tetraiodothyroacetic acid conjugated to glycolide-lactide copolymer; binds cell surface receptor for thyroid hormone on integrin alpha at cell membrane level and does not activate signal transduction
US7786090Mar 1, 2007Aug 31, 2010President And Fellows Of Harvard CollegeMethods and compositions for treating and preventing neurologic disorders
US7824704Aug 15, 2005Nov 2, 2010Surmodics, Inc.Controlled release bioactive agent delivery device
US7960606Jun 19, 2007Jun 14, 2011The J. David Gladstone InstitutesMouse model of chronic heart failure and coronary atherosclerosis regression
US7976862Aug 15, 2005Jul 12, 2011Surmodics, Inc.Longitudinal body; polymeric coating of polyalkyl(meth)acrylate and/or aromatic poly(meth)acrylate; and poly(ethylene-co-vinyl acetate); triamcinolone acetonide; drug delivery to eye
US8021680Apr 29, 2004Sep 20, 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US8034369Sep 12, 2005Oct 11, 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US8071134Sep 15, 2005Dec 6, 2011Ordway Research Institute, Inc.treating subjects having conditions related to angiogenesis; thyroid hormone, thyroid hormone analog, or polymeric forms thereof
US8084059Sep 15, 2006Dec 27, 2011Alza CorporationAntidepressant dosage form
US8163798Aug 12, 2003Apr 24, 2012Alza CorporationAdministering methylphenidate at an ascending release rate over an extended time period; therapeutic affect over long time period; hyperactivity/attention deficit disorder
US8211401Dec 4, 2009Jul 3, 2012Molecular Insight Pharmaceuticals, Inc.Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
US8211402Dec 4, 2009Jul 3, 2012Molecular Insight Pharmaceuticals, Inc.CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US8235047Mar 30, 2006Aug 7, 2012Conceptus, Inc.Methods and devices for deployment into a lumen
US8246974Apr 8, 2005Aug 21, 2012Surmodics, Inc.Medical devices and methods for producing the same
US8268887Oct 8, 2009Sep 18, 2012Feng XuDrug conjugates and methods of use thereof
US8518451Nov 25, 2009Aug 27, 2013Albany College of Pharmacy and Health ServicesThyroid hormone analogs and methods of use
US8562945Dec 4, 2009Oct 22, 2013Molecular Insight Pharmaceuticals, Inc.Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8629179Oct 19, 2009Jan 14, 2014Alza CorporationMethods and devices for providing prolonged drug therapy
US8668926Apr 11, 2007Mar 11, 2014Shaker A. MousaNanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8673344 *Nov 12, 2007Mar 18, 2014AbbVie Deutschland GmbH & Co. KGSolid dosage form with a film containing an active substance, as well as its method of production
US8707958Aug 1, 2012Apr 29, 2014Bayer Essure Inc.Methods and devices for deployment into a lumen
US8802240Jan 6, 2012Aug 12, 2014Nanopharmaceuticals LlcUses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US8821835Jun 13, 2013Sep 2, 2014Microspherix LlcFlexible and/or elastic brachytherapy seed or strand
US8840865Sep 30, 2013Sep 23, 2014Molecular Insight Pharmaceuticals, Inc.Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20100119583 *Nov 12, 2007May 13, 2010Abbott Gmbh & Co. KgSolid dosage form with a film containing an active substance, as well as its method of production
US20130189342 *Mar 16, 2011Jul 25, 2013Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US20130195950 *Mar 13, 2013Aug 1, 2013Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US20130195951 *Mar 13, 2013Aug 1, 2013Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
US20130202673 *Mar 13, 2013Aug 8, 2013Titan Pharmaceuticals, Inc.Heterogeneous implantable devices for drug delivery
DE2656387A1 *Dec 13, 1976Jun 30, 1977Hoffmann La RocheFeste pharmazeutische einheitsdosierungsform als darreichunsform eines medikaments sowie verfahren und anlage zu ihrer herstellung
DE3124981A1 *Jun 25, 1981Jan 13, 1983Ruhland Nachf Gmbh DrWirkstoffhaltige kollageneinlage zum einfuehren in knochen oder weichteile und verfahren zu deren herstellung
EP0010987A1 *Nov 5, 1979May 14, 1980Beecham Group PlcDevice for oral administration to a ruminant animal
EP0021758A1 *Jun 16, 1980Jan 7, 1981Beecham Group PlcVeterinary preparations for ruminant animals
EP0064841A1 *Apr 29, 1982Nov 17, 1982Smith and Nephew Associated Companies p.l.c.Applicators for pharmaceutically active agents, their preparation and use
EP0714912A2Jul 17, 1991Jun 5, 1996The Board Of Regents Of The University Of OklahomaGMP-140 derived lektin-like domain peptides and their ligands
EP0872234A2 *Apr 7, 1998Oct 21, 1998Röhm GmbhLaminar medical formulation
EP1920768A1 *Nov 10, 2006May 14, 2008Abbott GmbH & Co. KGSolid dosage form with a film containing an active substance, as well as its method of production
EP2133365A2Dec 26, 2007Dec 16, 2009Emory UniversityCompositions and methods for the treatment of infections and tumors
EP2194144A1Nov 15, 2005Jun 9, 2010Trustees Of Boston UniversityRoles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis
EP2335694A1Sep 15, 2004Jun 22, 2011Ordway Research Institute, Inc.Thyroid hormone analogs and methods of use.
EP2380872A1Jun 15, 2005Oct 26, 2011Polymedix, Inc.Polycationic compounds and uses thereof
EP2397155A1Jun 8, 2006Dec 21, 2011Dana Farber Cancer InstituteMethods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP2397156A1Jun 8, 2006Dec 21, 2011Dana-Farber Cancer Institute, Inc.Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway
EP2423331A2Mar 31, 2005Feb 29, 2012The General Hospital CorporationMethod to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2439284A1Mar 31, 2005Apr 11, 2012The General Hospital CorporationMethod to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2439285A1Mar 31, 2005Apr 11, 2012The General Hospital CorporationMethod to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2444038A2Feb 28, 2007Apr 25, 2012Conceptus, Inc.Devices for deployment into a lumen
EP2447375A2Mar 31, 2005May 2, 2012The General Hospital CorporationMethod to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2468883A1Dec 22, 2010Jun 27, 2012Pangaea Biotech S.L.Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2476707A1Nov 15, 2004Jul 18, 2012Children's Medical Center CorporationSelf-cleaving ribozymes and uses thereof
EP2492688A1Feb 23, 2011Aug 29, 2012Pangaea Biotech, S.A.Molecular biomarkers for predicting response to antitumor treatment in lung cancer
EP2662079A1May 10, 2012Nov 13, 2013Ordway Research Institute, Inc.Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
EP2706057A1Dec 4, 2009Mar 12, 2014Molecular Insight Pharmaceuticals, Inc.Bis(imidazolyl)compounds and radionuclide complexes
WO1991017745A1 *May 22, 1991Nov 28, 1991Southwest Res InstFilament system for delivering a medicament and method
WO1993021859A1 *Apr 26, 1993Nov 11, 1993Vincent Carmine GiampapaTissue-specific implantable therapeutic agent delivery system
WO1995023598A1 *Feb 28, 1995Sep 8, 1995Stevens Inst TechnologyControlled release microporous membranes
WO2001022947A2 *Sep 16, 2000Apr 5, 2001Krumme MarkusPreparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
WO2003097019A1 *Apr 29, 2003Nov 27, 2003Cuine-Backert Marie ElisabethMultilamellar system for the administration of active agents by means of ingestion
WO2004093962A1 *Mar 24, 2004Nov 4, 2004Cook IncMedical device with therapeutic agents.
WO2007097867A1 *Jan 25, 2007Aug 30, 2007Boston Scient Scimed IncExtendable rolled delivery system
WO2008056001A1 *Nov 12, 2007May 15, 2008Abbott Gmbh & Co KgSolid dosage form with a film containing an active substance, as well as its method of production
WO2010075332A1Dec 22, 2009Jul 1, 2010Charitable Leadership FoundationSmall molecule ligands of the integrin rgd recognition site and methods of use
WO2011058164A1Nov 15, 2010May 19, 2011Pangaea Biotech, S.A.Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2011061625A2Nov 19, 2010May 26, 2011Solis BiodyneCompositions for increasing polypeptide stability and activity, and related methods
WO2012085229A1Dec 22, 2011Jun 28, 2012Pangaea Biotech, S.L.Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012113819A1Feb 22, 2012Aug 30, 2012Pangaea Biotech, S.L.Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012149326A1 *Apr 27, 2012Nov 1, 2012Massachusetts Institute Of TechnologyLayer processing for pharmaceuticals
Classifications
U.S. Classification424/424, 424/484, 424/472, 424/443, 424/433, 424/426, 424/436, 424/427, 424/434, 424/435
International ClassificationA61K9/70, A61M31/00, A61K9/20, A61D7/00
Cooperative ClassificationA61D7/00, A61M31/002, A61K9/2072, A61K9/2086, A61K9/70
European ClassificationA61M31/00D, A61D7/00, A61K9/20K4, A61K9/70, A61K9/20K